Bank of America
NMRA icon

Bank of America’s Neumora Therapeutics NMRA Stock Holding History

Bank of America’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$106K – 8463
2024
Q4 		$106K Buy
+10,000
New +$120K ﹤0.01% 6373

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Bank of America's NMRA Position: Q1 2026 in Review

Bank of America increased its Neumora Therapeutics (NMRA) stake by 73% in Q1 2026, buying an estimated $193K and bringing the position to 176,927 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #5082.

Bank of America first reported a position in NMRA in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.01M in Q4 2024. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Bank of America held 176,927 shares of Neumora Therapeutics worth $345K as of Q1 2026.
  • Bank of America bought 74,518 Neumora Therapeutics shares in Q1 2026, an estimated $193K.
  • Neumora Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5082 holding.
  • Bank of America first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Bank of America's Neumora Therapeutics position peaked at $1.01M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.